|
Balance Sheet Cash Flow Statement 2000 Powell St., Ste. 800 Emeryville, CA 94608 CA Tel. 510-595-6000 Fax 510-595-6006 |
Type: Public
On the web:
http://www.ntii.com
Employees:
4
Employee growth: (87.9%)
Neurobiological Technologies focused on drugs targeting diseases of the brain and central nervous system. It managed the clinical trials for Xerecept, a potential treatment for the swelling that accompanies brain tumors; Celtic Pharma, a private equity firm that invests in late-stage drug compounds, owns marketing rights for Xerecept. In addition to its development efforts, Neurobiological Technologies earned royalties on US sales of memantine, an Alzheimer's treatment approved in the US and Europe. Primary candidate Viprinex, a potential treatment for ischemic stroke, failed in development trials. As a result, the company laid off 75% of its workforce and is preparing to liquidate.
Key numbers for fiscal year ending June, 2009:
Sales: $26.4M
One year growth: 78.5%
Net income: $3.1M
Officers:
Acting CEO and Director: William A. (Bill) Fletcher
VP, CFO, and Director: Biopharmaceuticals & Biotherapeutics
Competitors:
Concentric Medical
Forest Labs
Genentech
